pp-140 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Unresectable/metastatic melanoma (Stage III/IV) in combination with pembrolizumab
Clinical stage: Phase 2b
Modality: Biologic (personalised peptide neoantigen cancer vaccine)
Mechanism / Target: Patient-specific synthetic long peptides encoding private tumour neoantigens; activates neoantigen-specific CD4+ and CD8+ T cells; AI platform (RAVEN) predicts immunogenic neoantigens
Route / form: Subcutaneous injection (personalised per-patient manufacture)
Differentiation: AI-driven personalised approach; RAVEN platform provides high neoantigen prediction accuracy; combination with pembrolizumab exploits checkpoint relief in neoantigen-reactive T cells
Manufacturer #39171
Clinical-stage oncology company using AI to generate personalised neoantigen cancer vaccines. Combines genomics and proprietary AI to identify patient-specific tumour neoantigens. Advancing wholly owned pipeline in solid tumours in combination with checkpoint inhibitors.
None